Neogen Corp (Neogen) develops, manufactures, and markets products for food safety and animal safety. It provides diagnostic test kits, veterinary instruments, pharmaceuticals, vaccines, and genomics testing services. The company's product portfolio includes a wide range of diagnostic tests to detect toxins and pathogens in food, pharmaceuticals, rodenticides, disinfectants, vaccines and veterinary instruments. The company serves a wide array of customers, including food and feed producers, processors, laboratories, regulatory agencies, livestock producers, veterinarians, and companion animal owners.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Neogen's R&D arm focuses on the development and commercialization of innovative new products that advance its business strategy and enhance existing products. As of May 2026, Neogen had 89 scientists and support staff in its worldwide research and development group, including immunologists, chemists, geneticists, engineers, and microbiologists. The R&D team aligns with subject matter experts in academia, industry, and regulatory agencies to advance innovative scientific solutions benefiting the Food Safety and Animal Safety sectors. Neogen has ongoing development projects for several new and improved diagnostic tests and other complementary products for both the Food Safety and Animal Safety markets, with expectations for commercial availability during fiscal years 2027 and 2028. Certain technologies used in some products were acquired from or developed in collaboration with partners, independent scientists, governmental agencies, universities, and other third parties, with agreements providing for the payment of royalties based on sales of products using the pertinent licensed technology. Neogen has active development projects for various new diagnostic tests and complementary products for both the Food Safety and Animal Safety markets. Neogen holds around 157 US patents, along with 445 patents in countries other than the US, and 102 patent applications pending worldwide. In addition, Neogen's trademark portfolio consists of about 84 trademark registrations in the US and 449 trademark registrations in countries outside of the US. The company invested US$18.4 million in R&D activities in FY2026, which, as a percentage of its revenue, stood at 2.1%.